Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV913 Multiple Ascending Dose Study in Healthy Chinese Participants
NCT07507838Phase 1Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VV913 (4 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 6 days, Maximum Observed Plasma Concentration at 72 hours and 9 more. Started Apr 2026; status: recruiting.
02
Drugs
VV913
Beyond the preview
Go deeper on NCT07507838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507838.